Daniela Andreina Terribile
Overview
Explore the profile of Daniela Andreina Terribile including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magnavita N, Meraglia I, Terribile D
Int J Environ Res Public Health
. 2024 Aug;
21(8).
PMID: 39200667
Breast cancer (BC) is the most common invasive neoplasm and affects many women of working age. The return to work (RTW) of female survivors (BCSs) is associated with a better...
2.
Rocco N, Ghilli M, Curcio A, Bortul M, Burlizzi S, Cabula C, et al.
Eur J Surg Oncol
. 2024 Jan;
50(2):107954.
PMID: 38217946
Background: De-escalation of axillary surgery in breast cancer (BC) management began when sentinel lymph node biopsy (SLNB) replaced axillary lymph node dissection (ALND) as standard of care in patients with...
3.
Magnavita N, Di Prinzio R, Meraglia I, Vacca M, Arnesano G, Merella M, et al.
Healthcare (Basel)
. 2023 Aug;
11(16).
PMID: 37628540
Breast cancer (BC) is the most common invasive cancer in the world. Most BC survivors (BCSs) continue working while dealing with cancer-related disabilities. BCSs' return-to-work (RTW) after cancer treatment is...
4.
Franco A, Di Leone A, Fabi A, Belli P, Carbognin L, Gambaro E, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173916
Background: The diffusion of screening programs has resulted in a decrease of cT4 breast cancer diagnosis. The standard care for cT4 was neoadjuvant chemotherapy (NA), surgery, and locoregional or adjuvant...
5.
Mason E, Di Leone A, Franco A, DArchi S, Rianna C, Sanchez A, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428718
Oncoplastic level II breast-conserving surgery (OPS2) allows for wider excisions than standard breast-conserving surgery, but the literature on this technique in the treatment of DCIS is scarce. This study compares...
6.
Carbognin L, Accetta C, Di Giorgio D, Fuso P, Muratore M, Tiberi G, et al.
Curr Oncol
. 2022 Oct;
29(10):7218-7228.
PMID: 36290846
The prevention of chemotherapy-induced alopecia still represents an urgent need for every day clinical practice. In this regard, this prospective single-center study included breast cancer (BC) patients who underwent a...
7.
Oliverio A, Radice P, Colombo M, Angelo Paradiso , Tommasi S, Daniele A, et al.
Front Genet
. 2022 Mar;
13:820878.
PMID: 35356420
The female carriers of pathogenic variants (mutations) face a high lifetime risk of developing breast and/or ovarian cancer. However, the risk may differ depending on various genetic and non-genetic elements,...
8.
Di Leone A, Franco A, Terribile D, Magno S, Fabi A, Sanchez A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267583
Oncoplastic surgery level II techniques (OPSII) are used in patients with operable breast cancer. There is no evidence regarding their safety and efficacy after neoadjuvant chemotherapy (NAC). The aim of...
9.
Cognetti F, Masetti R, Fabi A, Bianchi G, Santini D, Rognone A, et al.
NPJ Breast Cancer
. 2021 May;
7(1):47.
PMID: 33953182
Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to...
10.
Franceschini G, Scardina L, Di Leone A, Terribile D, Sanchez A, Magno S, et al.
J Pers Med
. 2021 Mar;
11(2).
PMID: 33671712
Background: The aim of this study was to compare outcomes of immediate prosthetic breast reconstruction (IPBR) using traditional submuscular (SM) positioning of implants versus prepectoral (PP) positioning of micropolyurethane-foam-coated implants...